Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab.
about
The Changing Face of Clinical Trials in Psoriatic Arthritis.The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesPatient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA).Adaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in SingaporeEffect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Treat-to-target in spondyloarthritis: implications for clinical trial designs.A review of disease activity measures for psoriatic arthritis: what is the best approach?Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.Patient-Reported Outcomes in Psoriatic Arthritis.Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population.
P2860
Q30235002-F4A85EDD-D400-4F26-BE4D-696EE6CD8991Q33916770-0A1335DE-E887-4E82-90C8-8135044E4CC0Q35372388-75BF79D7-0D8A-41FC-8E44-638DE237AFC2Q36166729-89CED150-DCD8-4074-9183-696B194AE630Q37036355-864E985A-C73D-4D20-A5A3-2E46D3A6FB9CQ38223570-E50CA8F0-A946-4E32-A785-6AF0C96C8C65Q38236514-0B3654D5-221A-4667-9B43-1A7FFF09D75AQ38668527-1C452C9C-0D7F-4DF4-A85E-9923A814D759Q38690324-2D701DC0-29A4-4338-9768-E035E5BCED71Q38710469-C1572FEA-02FA-4904-990A-36D497383DF1Q38822369-70B684DB-3E1E-4CE3-93A9-D79DF0E4B054Q39233710-A6CFF2EF-F179-4A4E-B8E7-69F64F2B0BF7
P2860
Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Comparison of composite measur ...... entional study with golimumab.
@ast
Comparison of composite measur ...... entional study with golimumab.
@en
Comparison of composite measur ...... entional study with golimumab.
@en-gb
type
label
Comparison of composite measur ...... entional study with golimumab.
@ast
Comparison of composite measur ...... entional study with golimumab.
@en
Comparison of composite measur ...... entional study with golimumab.
@en-gb
prefLabel
Comparison of composite measur ...... entional study with golimumab.
@ast
Comparison of composite measur ...... entional study with golimumab.
@en
Comparison of composite measur ...... entional study with golimumab.
@en-gb
P2860
P356
P1476
Comparison of composite measur ...... entional study with golimumab.
@en
P2093
Arthur Kavanaugh
P2860
P304
P356
10.1002/ACR.22204
P577
2014-05-01T00:00:00Z